©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2017; 8(4): 320-328
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.320
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.320
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
Carmelo Tibaldi, Alice Lunghi, Editta Baldini, Division of Oncology, Department of Oncology, S. Luca Hospital, 55100 Lucca, Italy
Author contributions: Tibaldi C, Lunghi A and Baldini E contributed equally to this work.
Conflict-of-interest statement: None of the authors have any potential conflicts of interest associated with this research.
Correspondence to: Dr. Carmelo Tibaldi, Division of Oncology, Department of Oncology, S. Luca Hospital, Via Guglielmo Lippi Francesconi 1, 55100 Lucca, Italy. carmelo.tibaldi@uslnordovest.toscana.it
Telephone: +39-0583-055748 Fax: +39-0583-970161
Received: February 13, 2017
Peer-review started: February 14, 2017
First decision: April 14, 2017
Revised: May 15, 2017
Accepted: May 22, 2017
Article in press: May 24, 2017
Published online: August 10, 2017
Processing time: 175 Days and 6.9 Hours
Peer-review started: February 14, 2017
First decision: April 14, 2017
Revised: May 15, 2017
Accepted: May 22, 2017
Article in press: May 24, 2017
Published online: August 10, 2017
Processing time: 175 Days and 6.9 Hours
Core Tip
Core tip: Use of programmed cell death protein ligand 1 (PD-L1) assay to predict the outcomes of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors. This minireview underlines promises and pitfalls of the PD-L1 expression to predict the activity and efficacy of programmed cell death protein 1/PD-L1 inhibitors in NSCLC.